Introduction. Acute intermittent porphyria is a rare metabolic disorder of the hem biosynthetic pathway that can cause severe neurological symptoms involving the central, autonomic and peripheral nervous system. Diagnosis may be delayed due to variable symptoms that can mimic other diseases. Case report. A 23-year-old woman with abdominal pain, constipation, progressive development of quadriparesis and bulbar palsy was admitted to our intensive care unit two weeks after undergoing dental surgery. Preventive antibiotic therapy (erythromycin) and bromocriptine (due to cessation of breastfeeding) could represent precipitating factors for an acute attack of the disease. The diagnosis was confirmed by a high level of porphobilinogen and delta-aminolevulinic acid in urine. The patient was treated conservatively with high carbohydrate intake and human hemin, with a good treatment response. Two months after therapy, the patient was admitted to the Department of Physical Medicine and Rehabilitation and started physical therapy. There was a significant reduction of neurological manifestations at the follow-up examination after three months. Conclusion. Early diagnosis of acute intermittent porphyria is important for the preventiing of serious consequences and applying of prompt therapy. Further monitoring of patients is also important to avoid potential risk factors that can trigger a porphyria attack.
Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. New England Journal of Medicine. 2020;382(24):2289–301.
3.
Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine. 2019;380(6):549–58.
4.
Bylesjö I, Brekke OL, Prytz J, Skjeflo T, Salvesen R. Brain Magnetic Resonance Imaging White-Matter Lesions and Cerebrospinal Fluid Findings in Patients with Acute Intermittent Porphyria. European Neurology. 2004;51(1):1–5.
5.
Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. New England Journal of Medicine. 2017;377(9):862–72.
6.
Desnick RJ. The Porphyrias. In: Harrison’s Principles of Internal Medicine. 2001. p. 2261–7.
7.
Thunell S, Pomp E, Brun A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. British Journal of Clinical Pharmacology. 2007;64(5):668–79.
8.
Moore MR, Hift RJ. Drugs in the acute porphyrias-toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand. 1997;43(1):89–94.
9.
Gorchein A. Treatment of Parkinson’s disease in a patient with acute intermittent porphyria [letter]. British Journal of Clinical Pharmacology. 1995;40(1):105–6.
10.
Suh Y, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, et al. Neurological and neuropsychiatric manifestations of porphyria. International Journal of Neuroscience. 2019;129(12):1226–33.
11.
Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, et al. Acute Intermittent Porphyria: Predicted Pathogenicity ofHMBSVariants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. Human Mutation. 2016;37(11):1215–22.
12.
Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study. Molecular Genetics and Metabolism. 2016;119(3):278–83.
13.
Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. British Journal of Haematology. 2017;176(4):527–38.
14.
Kuo HC, Huang CC, Chu CC, Lee MJ, Chuang WL, Wu CL, et al. Neurological Complications of Acute Intermittent Porphyria. European Neurology. 2011;66(5):247–52.
15.
Gerischer LM, Scheibe F, Nümann A, Köhnlein M, Stölzel U, Meisel A. Acute porphyrias – A neurological perspective. Brain and Behavior. 2021;11(11).
16.
Ma L, Tian Y, Peng C, Zhang Y, Zhang S. Recent advances in the epidemiology and genetics of acute intermittent porphyria. Intractable & Rare Diseases Research. 2020;9(4):196–204.
17.
Gonzalez-Mosquera LF, Sonthalia S. Acute Intermittent Porphyria.
18.
Acute Hepatic Porphyria. Journal of Clinical and Translational Hepatology. 2015;3(1):17–26.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
